Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

YOU WONT BELIEVE: 2 - What They Never Told You

Zoetis Stock: Is ZTS Underperforming the Healthcare Sector?

Zoetis has recently underperformed the broader healthcare sector, but analysts remain optimistic about its long-term growth prospects.

Barchart

Is Zoetis Leading the Charge in Animal Health Innovation?

Zoetis Inc. (ZTS) reported impressive results for the third quarter of 2024, with strong revenue growth across diverse regions. The company’s future growth prospects appears promising, fueled by solid demand for its product offerings, operational expansions, and effective capital allocation. So, let’s determine whether Zoetis is an ideal addition to…

StockNews.com

3 'Strong Buy' Cyclical Stocks to Scoop Up Now

Brokerage firm Morgan Stanley is bullish on cyclical stocks.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

What Are Wall Street Analysts' Target Price for Zoetis Stock?

Zoetis has significantly underperformed the broader market over the past year, yet analysts remain bullish on the stock’s prospects.

Barchart

Zoetis' Q3 2024 Earnings: What to Expect

Zoetis will release its third-quarter earnings next month, and analysts expect a single-digit profit surge.

Barchart

Zoetis's Q3 2024 Earnings: What to Expect

Zoetis will release its third-quarter earnings next month, and analysts expect a single-digit profit surge.

Barchart

3 Defensive Dividend Stocks to Protect Against Pre-Election Volatility

As the U.S. presidential election nears, here are three defensive dividend-paying stocks to help shield your portfolio from pre-election volatility.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Is Zoetis Stock Underperforming the Dow?

Despite Zoetis’s underperformance relative to the Dow Jones Industrials Average over the past year, Wall Street analysts remain optimistic about the stock’s prospects.

Barchart

3 Pet Care Stocks With Tail-Wagging Potential

The pet care industry is expected to witness immense growth owing to a surge in pet adoptions, veterinary innovations, and rising disposable income. Thus, one could scoop up shares of fundamentally solid pet-care stocks with tail-wagging potential, like Zoetis (ZTS), Chewy (CHWY), and PetIQ (PETQ). Read more….

StockNews.com

Should You Buy Zoetis Amid Rising Pet Care Demand?

Zoetis (ZTS) continues to showcase its solid market position and commitment to innovation across its diverse portfolio, introducing advanced products that meet the evolving needs of animal health. Given its robust fundamentals and industry leadership, let’s find out if ZTS is a solid choice for those looking to invest in…

StockNews.com

Zoetis Stock: Is Wall Street Bullish or Bearish?

Despite Zoetis lagging behind the broader market over the past year, analysts still remain strongly bullish on the stock’s prospects.

Barchart

Zoetis Earnings Preview: What to Expect

As Zoetis is all set to announce its second-quarter earnings next month, analysts project a single-digit improvement in its bottom line.

Barchart

3 Pet Care Stocks to Watch

The pet care industry’s robust expansion is driven by rising disposable income, adoption of e-commerce platforms, and rising pet ownership. Therefore, investors could consider watching fundamentally sound pet care stocks, Zoetis (ZTS), IDEXX Laboratories (IDXX), and Chewy (CHWY). Keep reading.

StockNews.com

3 Top-Rated Healthcare Stocks With 20% to 35% Upside Potential

Amid a broader market rotation out of Big Tech stocks, investors can consider these three top-rated healthcare stocks with double-digit upside potential.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

3 Pharmaceutical Stocks With Blockbuster Potential

The pharmaceutical industry’s long-term growth is fueled by a surge in demand for personalized medicine, favorable R&D initiatives, and the adoption of cutting-edge technologies. Hence, it could be ideal to buy fundamentally solid pharma stocks Zoetis (ZTS), Viatris (VTRS), and Bristol-Myers Squibb (BMY) poised for blockbuster return potential. Keep reading….

Barchart

Is Zoetis Stock Underperforming the Nasdaq?

Despite Zoetis significantly trailing behind the Nasdaq Composite over the past three months, analysts seem extremely bullish on the stock’s prospects due to its robust product pipeline and global reach.

StockNews.com

4 Pharma Stocks to Watch for Surprising Gains in June

Amid growing demand for specialty drugs and increasing adoption of emerging technology in pharmaceutical manufacturing, the pharma industry is witnessing steady expansion. Therefore, quality pharmaceutical stocks Zoetis (ZTS), Viatris (VTRS), MEI Pharma (MEIP), and Amphastar Pharmaceuticals (AMPH) could be ideal additions to your watchlist. Keep reading….

StockNews.com

3 Pharma Stocks With May Potential

The pharma sector is poised for strong growth thanks to rising demand for personalized treatments, an aging population, advancements in pharma technology, and innovative approaches to drug discovery and manufacturing. Hence, investors could consider buying quality pharmaceutical stocks such as Zoetis (ZTS), Rigel Pharmaceuticals (RIGL), and Kamada (KMDA) with May…

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

5 High-Quality Stock Picks from Goldman Sachs

If you're wondering where to invest in these uncertain times, Goldman Sachs has dropped some hints with their top five stock picks that might just weather the storm.

StockNews.com

How To Painlessly Put Together A Profitable POWR Pairs Trade

Using the POWR Ratings to power profits on a POWR Pairs trade in Zoetis (ZTS) and Air Products (APD).

StockNews.com

4 Cutting-Edge Pharma Stocks for Portfolio Diversification

The pharmaceutical industry is expected to grow rapidly due to increasing healthcare demand, technological advancements, and rising demand for innovative drugs. Therefore, for portfolio diversification, investors could consider buying fundamentally strong pharmaceutical stocks such as Bayer (BAYRY), Procaps Group (PROC), ACADIA Pharmaceuticals (ACAD), and Zoetis (ZTS). Read more.

StockNews.com

Zoetis (ZTS): Analyzing Earnings for Potential Gains

Veterinary drugmaker Zoetis Inc. (ZTS) is all set to disclose its fiscal fourth-quarter earnings tomorrow. With the company boasting an impressive track record of consistently surpassing earnings expectations, would it be wise to acquire the shares of ZTS ahead of its earnings? Keep reading to find out….

StockNews.com

3 Growth Pharma Stocks to Guard Your Portfolio

The pharma industry is experiencing significant growth, fueled by rising demand for personalized medicines, a revolutionary wave of drug development and robust government support. Therefore, it could be wise to consider fundamentally strong pharma stocks Zoetis (ZTS), Bristol-Myers Squibb (BMY), and Teva Pharmaceutical Industries (TEVA) to guard your portfolio. Read…

StockNews.com

Pharma Buy, Hold, or Sell: 4 Stocks Worth Considering

The pharmaceutical industry is anticipated to thrive as demand grows and technology advances. However, given the macroeconomic uncertainties, let us analyze leading pharma stocks Zoetis (ZTS), Verano Holding (VRNOF), Canopy Growth (CGC) and SNDL (SNDL) to identify whether they are a Buy, Hold, or Sell. Read on.

StockNews.com

3 Top-Rated Pharma Stock Picks to Consider in the New Year

The pharmaceutical industry is expected to grow rapidly due to rising global medical needs and technological advancements. With the industry expected to thrive in the coming years, it could be wise to buy Zoetis (ZTS), AstraZeneca (AZN) and Taro Pharmaceutical (TARO) for steady returns. Read more.

1 2 3 4

People

Donald Trump

193,083 stories

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Medical Pharmaceuticals

BristolMyers Squibb Company

95 stories

Buy

94 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.